Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

Proceedings of the National Academy of Sciences of the United States of America - Tập 94 Số 7 - Trang 3336-3340 - 1997
Masahiko Tsujii1, Sunao Kawano1, Raymond N. DuBois1
1Departments of Medicine and Cell Biology, Molecular Toxicology Center, Vanderbilt University Medical Center and the Veterans Affairs Medical Center, Nashville, TN 37232; and First Department of Medicine, Osaka University School of Medicine, Osaka, Japan

Tóm tắt

Recent epidemiologic studies have shown a 40–50% reduction in mortality from colorectal cancer in individuals who take nonsteroidal antiinflammatory drugs on a regular basis compared with those not taking these agents. One property shared by all of these drugs is their ability to inhibit cyclooxygenase (COX), a key enzyme in the conversion of arachidonic acid to prostaglandins. Two isoforms of COX have been characterized, COX-1 and COX-2. COX-2 is expressed at high levels in intestinal tumors in humans and rodents. Human colon cancer cells (Caco-2) were permanently transfected with a COX-2 expression vector or the identical vector lacking the COX-2 insert. The Caco-2 cells, which constitutively expressed COX-2, acquired increased invasiveness compared with the parental Caco-2 cells or the vector transfected control cells. Biochemical changes associated with this phenotypic change included activation of metalloproteinase-2 and increased RNA levels for the membrane-type metalloproteinase. Increased invasiveness and prostaglandin production were reversed by treatment with sulindac sulfide, a known COX inhibitor. These studies demonstrate that constitutive expression of COX-2 can lead to phenotypic changes that alter the metastatic potential of colorectal cancer cells.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM199112053252301

M J Thun, M M Namboodiri, E E Calle, W D Flanders, C W J Heath Cancer Res 53, 1322–1327 (1993).

L J Marnett Cancer Res 52, 5575–5589 (1992).

10.1006/pmed.1995.1017

10.7326/0003-4819-121-4-199408150-00001

10.1056/NEJM199509073331001

10.1002/jso.2930240119

10.1016/0002-9610(89)90442-X

10.1056/NEJM199305063281805

10.1016/0959-8049(95)00137-8

10.1016/S0021-9258(18)53294-4

O Laneuville, D K Breuer, D L Dewitt, T Hla, C D Funk, W L Smith J Pharmacol Exp Ther 271, 927–934 (1994).

G P O’Neill, J A Mancini, S Kargman, J Yergey, M Y Kwan, J P Falgueyret, M Abramovitz, B P Kennedy, M Ouellet, W Cromlish, S Culp, J F Evans, A W Ford-Hutchinson, P J Vickers Mol Pharmacol 45, 245–254 (1994).

10.1042/bj3050479

10.1053/gast.1996.v111.pm8690211

10.1016/0016-5085(94)90246-1

S Kargman, G O’Neill, P Vickers, J Evans, J Mancini, S Jothy Cancer Res 55, 2556–2559 (1995).

H Sano, Y Kawahito, R L Wilder, A Hashiramoto, S Mukai, K Asai, S Kimura, H Kato, M Kondo, T Hla Cancer Res 55, 3785–3789 (1995).

10.1053/gast.1996.v110.pm8613017

10.1016/S0016-5085(96)70083-5

10.1016/0092-8674(95)90127-2

R N DuBois, M Tsujii, P Bishop, J A Awad, K Makita, A Lanahan Am J Physiol 266, G822–G827 (1994).

R N DuBois, J Shao, H Sheng, M Tsujii, R D Beauchamp Cancer Res 56, 733–737 (1996).

10.1016/0003-2697(80)90338-3

10.1083/jcb.118.3.727

10.1242/dev.114.2.447

10.1021/bi00591a005

A Albini, Y Iwamoto, H K Kleinman, G R Martin, S A Aaronson, J M Kozlowski, R N McEwan Cancer Res 47, 3239–3245 (1987).

A Melchiori, A Albini, J M Ray, W G Stetler-Stevenson Cancer Res 52, 2353–2356 (1992).

H Kobayashi, H Ohi, M Sugimura, H Shinohara, T Fujii, T Terao Cancer Res 52, 3610–3614 (1992).

10.1074/jbc.270.2.801

10.1074/jbc.270.10.5331

10.1016/0163-7258(93)90074-N

H Nomura, H Sato, M Seiki, M Mai, Y Okada Cancer Res 55, 3263–3266 (1995).

10.1074/jbc.270.39.23013

Thông tin
Thông tin xuất bản

Proceedings of the National Academy of Sciences of the United States of America

Tập 94 Số 7

3336-3340

Thông tin tác giả